Text-only version of the\
Recommended Adult Immunization Schedule

United States, October 2006--September 2007

Recommended Adult Immunization Schedule, by Vaccine and Age Group

**Vaccine: Tetanus, diphtheria, pertussis (Td/Tdap)**

Age group: 19-49 years -- Dosage: 1 dose Td booster every 10 years,
Substitute 1 dose of Tdap for Td

Age group: 50-64 years -- Dosage: 1 dose Td booster every 10 years,
Substitute 1 dose of Tdap for Td

Age group: greater than or equal to 65 years -- Dosage: 1 dose Td
booster every 10 years

For all persons in this category who meet the age requirements and who
lack evidence of immunity (e.g., lack documentation of vaccination or
have no evidence of prior infection)

Covered by the Vaccine Injury Compensation Program.

NOTE: These recommendations must be read with the footnotes.

Footnote 1:

Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination.
Adults with uncertain histories of a complete primary vaccination series
with diphtheria and tetanus toxoid--containing vaccines should begin or
complete a primary vaccination series. A primary series for adults is 3
doses; administer the first 2 doses at least 4 weeks apart and the third
dose 6--12 months after the second. Administer a booster dose to adults
who have completed a primary series and if the last vaccination was
received \>10 years previously. Tdap or tetanus and diphtheria (Td)
vaccine may be used; Tdap should replace a single dose of Td for adults
aged \<65 years who have not previously received a dose of Tdap (either
in the primary series, as a booster, or for wound management). Only one
of two Tdap products (Adacel® \[sanofi pasteur, Swiftwater,
Pennsylvania\]) is licensed for use in adults. If the person is pregnant
and received the last Td vaccination \>10 years previously, administer
Td during the second or third trimester; if the person received the last
Td vaccination in \<10 years, administer Tdap during the immediate
postpartum period. A one-time administration of 1-dose of Tdap with an
interval as short as 2 years from a previous Td vaccination is
recommended for postpartum women, close contacts of infants aged \<12
months, and all healthcare workers with direct patient contact. In
certain situations, Td can be deferred during pregnancy and Tdap
substituted in the immediate postpartum period, or Tdap can be given
instead of Td to a pregnant woman after an informed discussion with the
woman (see
[www.cdc.gov/nip/publications/acip-list.htm](http://www.cdc.gov/nip/publications/acip-list.htm)
). Consult the ACIP statement for recommendations for administering Td
as prophylaxis in wound management
([www.cdc.gov/mmwr/preview/mmwrhtml/00041645.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00041645.htm)
).

**Vaccine: Human papillomavirus (HPV)**

Age group: 19-49 years -- Dosage: 3 doses (females)

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Footnote 2:

Human papillomavirus (HPV) vaccination. HPV vaccination is recommended
for all females aged \<26 years who have not completed the vaccine
series. Ideally, vaccine should be administered before potential
exposure to HPV through sexual activity; however, women who are sexually
active should still be vaccinated. Sexually active women who have not
been infected with any of the HPV vaccine types receive the full benefit
of the vaccination. Vaccination is less beneficial for women who have
already been infected with one or more of the four HPV vaccine types. A
complete series consists of 3 doses. The second dose should be
administered 2 months after the first dose; the third dose should be
administered 6 months after the first dose. Vaccination is not
recommended during pregnancy. If a woman is found to be pregnant after
initiating the vaccination series, the remainder of the 3-dose regimen
should be delayed until after completion of the pregnancy.

**Vaccine: Measles, mumps, rubella (MMR)**

Age group: 19-49 years -- Dosage: 1 or 2 doses

For all persons in this category who meet the age requirements and who
lack evidence of immunity (e.g., lack documentation of vaccination or
have no evidence of prior infection)

Age group: 50-64 years -- Dosage: 1 dose

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Age group: greater than or equal to 65 years -- Dosage: 1 dose

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Covered by the Vaccine Injury Compensation Program.

NOTE: These recommendations must be read with the footnotes.

Footnote 3:

Measles, mumps, rubella (MMR) vaccination. Measles component: adults
born before 1957 can be considered immune to measles. Adults born during
or after 1957 should receive \>1 dose of MMR unless they have a medical
contraindication, documentation of \>1 dose, history of measles based on
healthcare provider diagnosis, or laboratory evidence of immunity. A
second dose of MMR is recommended for adults who 1) have been recently
exposed to measles or in an outbreak setting; 2) have been previously
vaccinated with killed measles vaccine; 3) have been vaccinated with an
unknown type of measles vaccine during 1963--1967; 4) are students in
postsecondary educational institutions; 5) work in a healthcare
facility; or 6) plan to travel internationally. Withhold MMR or other
measles-containing vaccines from HIV-infected persons with severe
immunosuppression. Mumps component: adults born before 1957 can
generally be considered immune to mumps. Adults born during or after
1957 should receive 1 dose of MMR unless they have a medical
contraindication, history of mumps based on healthcare provider
diagnosis, or laboratory evidence of immunity. A second dose of MMR is
recommended for adults who 1) are in an age group that is affected
during a mumps outbreak; 2) are students in postsecondary educational
institutions; 3) work in a healthcare facility; or 4) plan to travel
internationally. For unvaccinated healthcare workers born before 1957
who do not have other evidence of mumps immunity, consider giving 1 dose
on a routine basis and strongly consider giving a second dose during an
outbreak. Rubella component: administer 1 dose of MMR vaccine to women
whose rubella vaccination history is unreliable or who lack laboratory
evidence of immunity. For women of childbearing age, regardless of birth
year, routinely determine rubella immunity and counsel women regarding
congenital rubella syndrome. Do not vaccinate women who are pregnant or
who might become pregnant within 4 weeks of receiving vaccine. Women who
do not have evidence of immunity should receive MMR vaccine upon
completion or termination of pregnancy and before discharge from the
healthcare facility.

**Vaccine: Varicella**

Age group: 19-49 years -- Dosage: 2 doses (0, 4--8 wks)

For all persons in this category who meet the age requirements and who
lack evidence of immunity (e.g., lack documentation of vaccination or
have no evidence of prior infection)

Age group: 50-64 years -- Dosage: 2 doses (0, 4--8 wks)

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Covered by the Vaccine Injury Compensation Program.

NOTE: These recommendations must be read with the footnotes.

Footnote 4:

Varicella vaccination. All adults without evidence of immunity to
varicella should receive 2 doses of varicella vaccine. Special
consideration should be given to those who 1) have close contact with
persons at high risk for severe disease (e.g., healthcare workers and
family contacts of immunocompromised persons) or 2) are at high risk for
exposure or transmission (e.g., teachers of young children; child care
employees; residents and staff members of institutional settings,
including correctional institutions; college students; military
personnel; adolescents and adults living in households with children;
non-pregnant women of childbearing age; and international travelers).
Evidence of immunity to varicella in adults includes any of the
following: 1) documentation of 2 doses of varicella vaccine at least 4
weeks apart; 2) U.S.-born before 1980 (although for healthcare workers
and pregnant women, birth before 1980 should not be considered evidence
of immunity); 3) history of varicella based on diagnosis or verification
of varicella by a healthcare provider (for a patient reporting a history
of or presenting with an atypical case, a mild case, or both, healthcare
providers should seek either an epidemiologic link with a typical
varicella case or evidence of laboratory confirmation, if it was
performed at the time of acute disease); 4) history of herpes zoster
based on healthcare provider diagnosis; or 5) laboratory evidence of
immunity or laboratory confirmation of disease. Do not vaccinate women
who are pregnant or might become pregnant within 4 weeks of receiving
the vaccine. Assess pregnant women for evidence of varicella immunity.
Women who do not have evidence of immunity should receive dose 1 of
varicella vaccine upon completion or termination of pregnancy and before
discharge from the healthcare facility. Dose 2 should be administered
4--8 weeks after dose 1.

**Vaccine: Influenza**

Age group: 19-49 years -- Dosage: 1 dose annually

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Age group: 50-64 years -- Dosage: 1 dose annually

For all persons in this category who meet the age requirements and who
lack evidence of immunity (e.g., lack documentation of vaccination or
have no evidence of prior infection)

Age group: greater than or equal to 65 years -- Dosage: 1 dose annually

For all persons in this category who meet the age requirements and who
lack evidence of immunity (e.g., lack documentation of vaccination or
have no evidence of prior infection)

Covered by the Vaccine Injury Compensation Program.

NOTE: These recommendations must be read with the footnotes.

Footnote 5:

5\. Influenza vaccination. Medical indications: chronic disorders of the
cardiovascular or pulmonary systems, including asthma; chronic metabolic
diseases, including diabetes mellitus, renal dysfunction,
hemoglobinopathies, or immunosuppression (including immunosuppression
caused by medications or HIV); any condition that compromises
respiratory function or the handling of respiratory secretions or that
can increase the risk of aspiration (e.g., cognitive dysfunction, spinal
cord injury, or seizure disorder or other neuromuscular disorder); and
pregnancy during the influenza season. No data exist on the risk for
severe or complicated influenza disease among persons with asplenia;
however, influenza is a risk factor for secondary bacterial infections
that can cause severe disease among persons with asplenia. Occupational
indications: healthcare workers and employees of long-term--care and
assisted living facilities. Other indications: residents of nursing
homes and other long-term--care and assisted living facilities; persons
likely to transmit influenza to persons at high risk (i.e., in-home
household contacts and caregivers of children aged 0--59 months, or
persons of all ages with high-risk conditions); and anyone who would
like to be vaccinated. Healthy, nonpregnant persons aged 5--49 years
without high-risk medical conditions who are not contacts of severely
immunocompromised persons in special care units can receive either
intranasally administered influenza vaccine (FluMist®) or inactivated
vaccine. Other persons should receive the inactivated vaccine.

**Vaccine: Pneumococcal (polysaccharide)**

Age group: 19-49 years -- Dosage: 1--2 doses

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Age group: 50-64 years -- Dosage: 1--2 doses

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Age group: greater than or equal to 65 years --1 dose

For all persons in this category who meet the age requirements and who
lack evidence of immunity (e.g., lack documentation of vaccination or
have no evidence of prior infection)

Footnotes 6 and 7:

Footnote 6: Pneumococcal polysaccharide vaccination. Medical
indications: chronic disorders of the pulmonary system (excluding
asthma); cardiovascular diseases; diabetes mellitus; chronic liver
diseases, including liver disease as a result of alcohol abuse (e.g.,
cirrhosis); chronic renal failure or nephrotic syndrome; functional or
anatomic asplenia (e.g., sickle cell disease or splenectomy \[if
elective splenectomy is planned, vaccinate at least 2 weeks before
surgery\]); immunosuppressive conditions (e.g., congenital
immunodeficiency, HIV infection \[vaccinate as close to diagnosis as
possible when CD4 cell counts are highest\], leukemia, lymphoma,
multiple myeloma, Hodgkin disease, generalized malignancy, or organ or
bone marrow transplantation); chemotherapy with alkylating agents,
antimetabolites, or high-dose, long-term corticosteroids; and cochlear
implants. Other indications: Alaska Natives and certain American Indian
populations and residents of nursing homes or other long-term--care
facilities.

Footnote 7: Revaccination with pneumococcal polysaccharide vaccine.
Onetime revaccination after 5 years for persons with chronic renal
failure or nephrotic syndrome; functional or anatomic asplenia (e.g.,
sickle cell disease or splenectomy); immunosuppressive conditions (e.g.,
congenital immunodeficiency, HIV infection, leukemia, lymphoma, multiple
myeloma, Hodgkin disease, generalized malignancy, or organ or bone
marrow transplantation); or chemotherapy with alkylating agents,
antimetabolites, or high-dose, long-term corticosteroids. For persons
aged \>65 years, one-time revaccination if they were vaccinated \>5
years previously and were aged \<65 years at the time of primary
vaccination.

**Vaccine: Hepatitis A**

Age group: 19-49 years -- Dosage: 2 doses (0, 6--12 mos, or 0, 6--18
mos)

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Age group: 50-64 years -- Dosage: 2 doses (0, 6--12 mos, or 0, 6--18
mos)

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Age group: greater than or equal to 65 years -- Dosage: 2 doses (0,
6--12 mos, or 0, 6--18 mos)

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Covered by the Vaccine Injury Compensation Program.

NOTE: These recommendations must be read with the footnotes.

Footnote 8:

Hepatitis A vaccination. Medical indications: persons with chronic liver
disease and persons who receive clotting factor concentrates. Behavioral
indications: men who have sex with men and persons who use illegal
drugs. Occupational indications: persons working with hepatitis A virus
(HAV)--infected primates or with HAV in a research laboratory setting.
Other indications: persons traveling to or working in countries that
have high or intermediate endemicity of hepatitis A (a list of countries
is available at
[www.cdc.gov/travel/diseases.htm](http://www.cdc.gov/travel/diseases.htm)
) and any person who would like to obtain immunity. Current vaccines
should be administered in a 2-dose schedule at either 0 and 6--12
months, or 0 and 6--18 months. If the combined hepatitis A and hepatitis
B vaccine is used, administer 3 doses at 0, 1, and 6 months.

**Vaccine: Hepatitis B**

Age group: 19-49 years -- Dosage: 3 doses (0, 1--2, 4--6 mos)

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Age group: 50-64 years -- Dosage: 3 doses (0, 1--2, 4--6 mos)

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Age group: greater than or equal to 65 years -- Dosage: 3 doses (0,
1--2, 4--6 mos)

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Covered by the Vaccine Injury Compensation Program.

NOTE: These recommendations must be read with the footnotes.

Footnote 9:

Hepatitis B vaccination. Medical indications: persons with endstage
renal disease, including patients receiving hemodialysis; persons
seeking evaluation or treatment for a sexually transmitted disease
(STD); persons with HIV infection; persons with chronic liver disease;
and persons who receive clotting factor concentrates. Occupational
indications: healthcare workers and public-safety workers who are
exposed to blood or other potentially infectious body fluids. Behavioral
indications: sexually active persons who are not in a long-term,
mutually monogamous relationship (i.e., persons with \>1 sex partner
during the previous 6 months); current or recent injection-drug users;
and men who have sex with men. Other indications: household contacts and
sex partners of persons with chronic hepatitis B virus (HBV) infection;
clients and staff members of institutions for persons with developmental
disabilities; all clients of STD clinics; international travelers to
countries with high or intermediate prevalence of chronic HBV infection
(a list of countries is available at www.cdc.gov/travel/diseases.htm);
and any adult seeking protection from HBV infection. Settings where
hepatitis B vaccination is recommended for all adults: STD treatment
facilities; HIV testing and treatment facilities; facilities providing
drug-abuse treatment and prevention services; healthcare settings
providing services for injection-drug users or men who have sex with
men; correctional facilities; end-stage renal disease programs and
facilities for chronic hemodialysis patients; and institutions and
nonresidential daycare facilities for persons with developmental
disabilities. Special formulation indications: for adult patients
receiving hemodialysis and other immunocompromised adults, 1 dose of 40
µg/mL (Recombivax HB®) or 2 doses of 20 µg/mL (Engerix-B®).

**Vaccine: Meningococcal**

Age group: 19-49 years -- Dosage: 1 or more doses

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Age group: 50-64 years -- Dosage: 1 or more doses

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Age group: greater than or equal to 65 years -- Dosage: 1 or more doses

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Footnote 10:

10\. Meningococcal vaccination. Medical indications: adults with
anatomic or functional asplenia, or terminal complement component
deficiencies. Other indications: first-year college students living in
dormitories; microbiologists who are routinely exposed to isolates of
Neisseria meningitidis; military recruits; and persons who travel to or
live in countries in which meningococcal disease is hyperendemic or
epidemic (e.g., the "meningitis belt" of sub-Saharan Africa during the
dry season \[December--June\]), particularly if their contact with local
populations will be prolonged. Vaccination is required by the government
of Saudi Arabia for all travelers to Mecca during the annual Hajj.
Meningococcal conjugate vaccine is preferred for adults with any of the
preceding indications who are aged \<55 years, although meningococcal
polysaccharide vaccine (MPSV4) is an acceptable alternative.
Revaccination after 5 years might be indicated for adults previously
vaccinated with MPSV4 who remain at high risk for infection (e.g.,
persons residing in areas in which disease is epidemic).

This schedule indicates the recommended age groups and medical
indications for routine administration of currently licensed vaccines
for persons aged \>19 years, as of October 1, 2006. Licensed combination
vaccines may be used whenever any components of the combination are
indicated and when the vaccine's other components are not
contraindicated. For detailed recommendations on all vaccines, including
those used primarily for travelers or that are issued during the year,
consult the manufacturers' package inserts and the complete statements
from the Advisory Committee on Immunization Practices
([www.cdc.gov/nip/publications/acip-list.htm](http://www.cdc.gov/nip/publications/acip-list.htm)
).

Report all clinically significant postvaccination reactions to the
Vaccine Adverse Event Reporting System (VAERS). Reporting forms and
instructions on filing a VAERS report are available at www.vaers.hhs.gov
or by telephone, 800-822-7967.

Information on how to file a Vaccine Injury Compensation Program claim
is available at
[www.hrsa.gov/vaccinecompensation](http://www.hrsa.gov/vaccinecompensation)
or by telephone, 800-338-2382. To file a claim for vaccine injury,
contact the U.S. Court of Federal Claims, 717 Madison Place, N.W.,
Washington, D.C. 20005; telephone, 202-357-6400.

Additional information about the vaccines in this schedule and
contraindications for vaccination is also available at
[www.cdc.gov/nip](http://www.cdc.gov/nip) or from the CDC-INFO Contact
Center at 800-CDC-INFO (800-232-4636) in English and Spanish, 24 hours a
day, 7 days a week.

Recommended Adult Immunization Schedule, by Vaccine and Medical and
Other Indications

-   Indication

-   Pregnancy

-   Congenital immunodeficiency, leukemia, (Footnote 11: Selected
    conditions for which Haemophilus influenzae type b (Hib) vaccine may
    be used. Hib conjugate vaccines are licensed for children aged 6
    weeks--71 months. No efficacy data are available on which to base a
    recommendation concerning use of Hib vaccine for older children and
    adults with the chronic conditions associated with an increased risk
    for Hib disease. However, studies suggest good immunogenicity in
    patients who have sickle cell disease, leukemia, or HIV infection or
    who have had splenectomies; administering vaccine to these patients
    is not contraindicated.) lymphoma, generalized malignancy,
    cerebrospinal fluid leaks, therapy with alkylating agents,
    antimetabolites, radiation, or high-dose, long-term corticosteroids

-   Diabetes, heart disease, chronic pulmonary disease, chronic
    alcoholism

-   Asplenia (Footnote 11: Selected conditions for which Haemophilus
    influenzae type b (Hib) vaccine may be used. Hib conjugate vaccines
    are licensed for children aged 6 weeks--71 months. No efficacy data
    are available on which to base a recommendation concerning use of
    Hib vaccine for older children and adults with the chronic
    conditions associated with an increased risk for Hib disease.
    However, studies suggest good immunogenicity in patients who have
    sickle cell disease, leukemia, or HIV infection or who have had
    splenectomies; administering vaccine to these patients is not
    contraindicated.) (including elective splenectomy and terminal
    complement component deficiencies)

-   Chronic liver disease, recipients of clotting factor concentrates

```{=html}
<!-- -->
```
-   Kidney failure, end-stage renal disease, recipients of hemodialysis

```{=html}
<!-- -->
```
-   Human immunodeficiency virus (HIV) infection Footnote 3: Measles,
    mumps, rubella (MMR) vaccination. Measles component: adults born
    before 1957 can be considered immune to measles. Adults born during
    or after 1957 should receive \>1 dose of MMR unless they have a
    medical contraindication, documentation of \>1 dose, history of
    measles based on healthcare provider diagnosis, or laboratory
    evidence of immunity. A second dose of MMR is recommended for adults
    who 1) have been recently exposed to measles or in an outbreak
    setting; 2) have been previously vaccinated with killed measles
    vaccine; 3) have been vaccinated with an unknown type of measles
    vaccine during 1963--1967; 4) are students in postsecondary
    educational institutions; 5) work in a healthcare facility; or 6)
    plan to travel internationally. Withhold MMR or other
    measles-containing vaccines from HIV-infected persons with severe
    immunosuppression. Mumps component: adults born before 1957 can
    generally be considered immune to mumps. Adults born during or after
    1957 should receive 1 dose of MMR unless they have a medical
    contraindication, history of mumps based on healthcare provider
    diagnosis, or laboratory evidence of immunity. A second dose of MMR
    is recommended for adults who 1) are in an age group that is
    affected during a mumps outbreak; 2) are students in postsecondary
    educational institutions; 3) work in a healthcare facility; or 4)
    plan to travel internationally. For unvaccinated healthcare workers
    born before 1957 who do not have other evidence of mumps immunity,
    consider giving 1 dose on a routine basis and strongly consider
    giving a second dose during an outbreak. Rubella component:
    administer 1 dose of MMR vaccine to women whose rubella vaccination
    history is unreliable or who lack laboratory evidence of immunity.
    For women of childbearing age, regardless of birth year, routinely
    determine rubella immunity and counsel women regarding congenital
    rubella syndrome. Do not vaccinate women who are pregnant or who
    might become pregnant within 4 weeks of receiving vaccine. Women who
    do not have evidence of immunity should receive MMR vaccine upon
    completion or termination of pregnancy and before discharge from the
    healthcare facility), (Footnote 11: Selected conditions for which
    Haemophilus influenzae type b (Hib) vaccine may be used. Hib
    conjugate vaccines are licensed for children aged 6 weeks--71
    months. No efficacy data are available on which to base a
    recommendation concerning use of Hib vaccine for older children and
    adults with the chronic conditions associated with an increased risk
    for Hib disease. However, studies suggest good immunogenicity in
    patients who have sickle cell disease, leukemia, or HIV infection or
    who have had splenectomies; administering vaccine to these patients
    is not contraindicated.)

```{=html}
<!-- -->
```
-   Healthcare workers

Vaccine

Tetanus, diphtheria, pertussis (Td/Tdap)1,\*

Human papillomavirus (HPV)2

Measles, mumps, rubella (MMR)3,\*

Varicella4,\*

Influenza5,\*

Pneumococcal (polysaccharide)6,7

Hepatitis A8,\*

Hepatitis B9,\*

Meningococcal10

1 dose Td booster every 10 yrs

Substitute 1 dose of Tdap for Td

3 doses for females through age 26 yrs (0, 2, 6 mos)

1 or 2 doses

2 doses (0, 4--8 wks)

2 doses

1 dose annually

1 dose annually

1 dose annually

1--2 doses

1--2 doses

1--2 doses

2 doses (0, 6--12 mos, or 0, 6--18 mos)

2 doses

2 doses (0, 6--12 mos, or 0, 6--18 mos)

3 doses (0, 1--2, 4--6 mos)

3 doses (0, 1--2, 4--6 mos)

1 dose

1 dose

1 dose

\*Covered by the Vaccine Injury Compensation Program. NOTE: These
recommendations must be read with the footnotes (see reverse).

For all persons in this category who meet the age requirements and who
lack evidence of immunity (e.g., lack documentation of vaccination or
have no evidence of prior infection)

Recommended if some other risk factor is present (e.g., on the basis of
medical, occupational, lifestyle, or other indications)

Contraindicated

Approved by the Advisory Committee on Immunization Practices, the
American College of Obstetricians and Gynecologists, the American
Academy of Family Physicians, and the American College of Physicians

HHS logo

CDC logo

Department of Health and Human Services

Centers for Disease Control and Prevention